NYSE$TEVA

Teva Pharmaceutical Industries ADR · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Reported strong results driven by increased demand for generics, OTC, and respiratory products, along with operating and net profit growth, contributing to strong free cash flow and reduced net debt.

Teva Pharmaceutical Industries Ltd. reported strong first quarter 2020 results, with revenues of $4.4 billion, GAAP diluted EPS of $0.06, non-GAAP diluted EPS of $0.76, and free cash flow of $551 million. The company reaffirmed its full-year 2020 business outlook.

  • Revenues increased by 5% due to higher generics and OTC sales in Europe, AUSTEDO and Anda in North America, and growth in International Markets.
  • GAAP gross profit increased by 11% to $2,063 million, with a gross profit margin of 47.3%.
  • Non-GAAP operating income increased by 22% to $1,244 million.
  • Free cash flow was $551 million, driven by higher operating profit and significant consumption of inventories.

Headline financials

Total Revenue

$4.36B

Previous: $4.3B+1.4%
EPS (adj)

$0.76

Previous: $0.60+26.7%
Capital Expenditures

-$128M

Previous: -$125M-2.4%
Free Cash Flow

-$59M

Previous: -$230M+74.3%
Net Income

$69M

Previous: -$105M+165.7%
Operating Income

$191M

Previous: $134M+42.5%
Gross Profit

$2.06B

Previous: $1.86B+11.2%
Cash & Equivalents

$1.8B

Previous: $1.97B-8.6%
Total Assets

$55.3B

Previous: $59.9B-7.6%
Stock-Based Comp

$30M

Previous: $34M-11.8%

Revenue & EPS history

Teva · Revenue · Quarterly

$4.36B

Q1 2020+1.4%vs Q1 2019
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Teva · $2.27B total across 3 segments · Q1 2020

  • Europe
    $1.4B
  • International Markets
    $565M
  • Other Activities
    $307M

Forward guidance

Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+0.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+0.7%

Avg return

30 days after

51%

38 / 74 earnings

Positive

+27.1%

Q2 2022

Best reaction

-34.1%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+11.9%+11.7%
Q4 2025+2.1%+9.2%+4.1%
Q3 2025+20.4%+18.6%+39.1%
Q2 2025+1.8%-5.1%+11.1%
Q1 2025+8.9%+11.4%+10.2%
Q4 2024-13.9%-19.4%-23.5%
Q3 2024-6.8%-7.5%-7.7%
Q2 2024+6.9%+1.6%+15.0%
Q1 2024+14.7%+21.0%+20.6%
Q4 2023+6.2%+5.5%+15.1%
Q3 2023-3.0%-2.4%+8.6%
Q2 2023+15.4%+16.2%+18.7%
Q1 2023-9.8%-11.3%-19.5%
Q4 2022-9.8%-5.4%-16.3%
Q3 2022-3.3%+3.7%-1.1%
Q2 2022+27.1%+30.5%+37.6%
Q1 2022-2.3%-8.1%+11.6%
Q4 2021+6.3%+2.8%-9.8%
Q3 2021-7.0%-1.7%-9.6%
Q2 2021+8.6%+10.4%+4.8%
Q1 2021+2.6%+4.2%+0.3%
Q4 2020-11.8%-13.2%-15.8%
Q3 2020-1.0%+4.5%+11.6%
Q2 2020+3.0%+0.6%-22.1%
Q1 2020+7.7%+9.0%+22.5%
Q4 2019+1.9%-0.9%-31.9%
Q3 2019+14.8%+18.6%+22.5%
Q2 2019+3.3%-0.6%-0.7%
Q1 2019-0.3%-4.1%-43.2%
Q4 2018-9.6%-6.0%-13.7%
Q3 2018+13.1%+15.6%+7.8%
Q2 2018-7.1%-2.5%-4.0%
Q1 2018-4.1%+1.6%+17.7%
Q4 2017-10.7%-11.2%-8.0%
Q3 2017-18.7%-16.6%+8.8%
Q2 2017-34.1%-16.2%-39.4%
Q1 2017+1.7%+1.3%-3.6%
Q4 2016+8.4%+9.4%+6.7%
Q3 2016-7.2%-6.0%-10.5%
Q2 2016+1.2%-6.2%-8.8%
Q1 2016+5.2%+1.7%+10.8%
Q4 2015-2.0%
Q3 2015-5.1%
Q2 2015-2.6%
Q1 2015+0.1%
Q3 2014+3.6%
Q4 2014+2.0%
Q2 2014-1.6%
Q1 2014+2.0%
Q4 2013-1.9%
Q3 2013-1.5%
Q2 2013-2.0%
Q1 2013+1.0%
Q4 2012+1.4%
Q3 2012+2.6%
Q2 2012-3.3%
Q1 2012-5.4%
Q4 2011+2.5%
Q3 2011+7.0%
Q2 2011+1.9%
Q1 2011+5.6%
Q4 2010+0.4%
Q3 2010+0.3%
Q2 2010-3.4%
Q1 2010+0.9%
Q4 2007+1.2%
Q4 2009+1.2%
Q3 2008-1.4%
Q3 2009-1.4%
Q2 2008-0.8%
Q2 2009-0.8%
Q1 2009-0.6%
Q1 2008-0.6%
Q4 2008-0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro